Drug Addiction – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Drug Addiction – Pipeline Review, H1 2017’, provides an overview of the Drug Addiction pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Drug Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Drug Addiction and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Drug Addiction

The report reviews pipeline therapeutics for Drug Addiction by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Drug Addiction therapeutics and enlists all their major and minor projects

The report assesses Drug Addiction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Drug Addiction

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Drug Addiction

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Drug Addiction pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Addex Therapeutics Ltd

Aelis Farma SAS

Aphios Corp

Astraea Therapeutics LLC

BioCorRx Inc

Cerecor Inc

Chiesi Farmaceutici SpA

Curemark LLC

Embera NeuroTherapeutics Inc

F. Hoffmann-La Roche Ltd

Foresee Pharmaceuticals LLC

Heptares Therapeutics Ltd

Immunovaccine Inc

Indivior Plc

InterveXion Therapeutics LLC

Intra-Cellular Therapies Inc

Kyorin Pharmaceutical Co Ltd

Kyowa Hakko Kirin Co Ltd

MedRev Pharma

NLS Pharma Group

Omeros Corp

Opiant Pharmaceuticals Inc

Orexigen Therapeutics Inc

P2D Bioscience

Saniona AB

Savant HWP Inc

Stada Arzneimittel AG

Teva Pharmaceutical Industries Ltd

Zynerba Pharmaceuticals Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Drug Addiction - Overview 8

Drug Addiction - Therapeutics Development 9

Pipeline Overview 9

Pipeline by Companies 10

Pipeline by Universities/Institutes 13

Products under Development by Companies 15

Products under Development by Universities/Institutes 18

Drug Addiction - Therapeutics Assessment 20

Assessment by Target 20

Assessment by Mechanism of Action 23

Assessment by Route of Administration 26

Assessment by Molecule Type 28

Drug Addiction - Companies Involved in Therapeutics Development 30

Addex Therapeutics Ltd 30

Aelis Farma SAS 30

Aphios Corp 31

Astraea Therapeutics LLC 31

BioCorRx Inc 32

Cerecor Inc 32

Chiesi Farmaceutici SpA 33

Curemark LLC 33

Embera NeuroTherapeutics Inc 34

F. Hoffmann-La Roche Ltd 34

Foresee Pharmaceuticals LLC 35

Heptares Therapeutics Ltd 35

Immunovaccine Inc 36

Indivior Plc 36

InterveXion Therapeutics LLC 37

Intra-Cellular Therapies Inc 37

Kyorin Pharmaceutical Co Ltd 38

Kyowa Hakko Kirin Co Ltd 38

MedRev Pharma 39

NLS Pharma Group 39

Omeros Corp 40

Opiant Pharmaceuticals Inc 40

Orexigen Therapeutics Inc 41

P2D Bioscience 41

Saniona AB 42

Savant HWP Inc 42

Stada Arzneimittel AG 43

Teva Pharmaceutical Industries Ltd 43

Zynerba Pharmaceuticals Inc 44

Drug Addiction - Drug Profiles 45

(acetaminophen + hydrocodone bitartrate + Respiratory Drug) - Drug Profile 45

(hydrocodone bitartrate + naltrexone hydrochloride) - Drug Profile 46

(metyrapone + oxazepam) - Drug Profile 47

18-MC - Drug Profile 50

ADX-71441 - Drug Profile 52

ADX-71743 - Drug Profile 56

ADX-88178 - Drug Profile 57

AEF-0117 - Drug Profile 60

ANS-6637 - Drug Profile 61

AT-076 - Drug Profile 62

AT-089 - Drug Profile 63

AT-1001 - Drug Profile 64

AT-212 - Drug Profile 65

Biologic to Agonize TLR4 for Drug Addiction - Drug Profile 66

cannabidiol - Drug Profile 67

CERC-501 - Drug Profile 68

CM-1212 - Drug Profile 71

dronabinol - Drug Profile 72

dronabinol - Drug Profile 73

Drug for Dependence - Drug Profile 74

Enzyme for Cocaine Addiction - Drug Profile 75

EORA-101 - Drug Profile 76

FP-004 - Drug Profile 77

Gene Therapy to Activate Cocaine Hydrolase for Cocaine Abuse - Drug Profile 78

h2E-2 - Drug Profile 79

ibudilast - Drug Profile 80

istradefylline - Drug Profile 90

ITI-333 - Drug Profile 93

IXT-m200 - Drug Profile 94

JDTic - Drug Profile 96

JQ-1 - Drug Profile 97

KDAC-0001 - Drug Profile 98

levofacetoperane - Drug Profile 99

lofexidine hydrochloride - Drug Profile 100

LT-22 - Drug Profile 102

MC-100093 - Drug Profile 103

naloxone hydrochloride - Drug Profile 104

naltrexone hydrochloride SR - Drug Profile 107

NS-2359 - Drug Profile 109

OMS-405 - Drug Profile 111

OMS-527 - Drug Profile 113

OREX-1019 - Drug Profile 115

OREX-1038 - Drug Profile 116

RBP-8000 - Drug Profile 117

Recombinant Enzyme for Cocaine Abuse - Drug Profile 119

RO-5256390 - Drug Profile 120

Small Molecule to Activate Kappa Opioid Receptor for CNS - Drug Profile 121

Small Molecule to Antagonize Dopamine D1, D2 and D3 Receptors for Cocaine Use Disorder and Schizophrenia - Drug Profile 122

Small Molecule to Antagonize Mu Opioid Receptor for Drug Abuse, Alcohol Addiction and OIC - Drug Profile 123

Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders - Drug Profile 124

Small Molecules for Neonatal Abstinence Syndrome - Drug Profile 125

Small Molecules to Agonize 5HT2C and Antagonize 5HT2A, 5HT2B for Psychiatric Disorders - Drug Profile 126

Small Molecules to Block VMAT2 for Methamphetamine Addiction - Drug Profile 127

Small Molecules to Inhibit CB1 Receptor for Cannabinoid Abuse and Drug Addiction - Drug Profile 128

Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders - Drug Profile 129

Small Molecules to Inhibit Dopamine, Serotonin, Norepinephrine Transporters for Central Nervous System Disorders - Drug Profile 130

Small Molecules to Inhibit Kappa Opioid Receptor for CNS - Drug Profile 131

Small Molecules to Scavenge Free Radicals for Oxidative Stress Related Disorders - Drug Profile 132

Small Molecules to Target 5HT2 for CNS Disorders and Obesity - Drug Profile 133

Small Molecules to Target Nicotinic Acetylcholine Receptors for Drug Addiction and Drug Abuse - Drug Profile 134

Synthetic Peptide to Target Kappa Opioid Receptors for Drug Addiction - Drug Profile 135

Vaccine for Cocaine Addiction - Drug Profile 136

Vaccine for Drug Abuse - Drug Profile 138

Vaccine for Methamphetamine Abuse - Drug Profile 139

Vaccine for Methamphetamine Addiction - Drug Profile 141

VU-0463841 - Drug Profile 142

Drug Addiction - Dormant Projects 143

Drug Addiction - Discontinued Products 146

Drug Addiction - Product Development Milestones 147

Featured News & Press Releases 147

Appendix 159

Methodology 159

Coverage 159

Secondary Research 159

Primary Research 159

Expert Panel Validation 159

Contact Us 159

Disclaimer 160

List of Tables

List of Tables

Number of Products under Development for Drug Addiction, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Drug Addiction – Pipeline by Addex Therapeutics Ltd, H1 2017

Drug Addiction – Pipeline by Aelis Farma SAS, H1 2017

Drug Addiction – Pipeline by Aphios Corp, H1 2017

Drug Addiction – Pipeline by Astraea Therapeutics LLC, H1 2017

Drug Addiction – Pipeline by BioCorRx Inc, H1 2017

Drug Addiction – Pipeline by Cerecor Inc, H1 2017

Drug Addiction – Pipeline by Chiesi Farmaceutici SpA, H1 2017

Drug Addiction – Pipeline by Curemark LLC, H1 2017

Drug Addiction – Pipeline by Embera NeuroTherapeutics Inc, H1 2017

Drug Addiction – Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Drug Addiction – Pipeline by Foresee Pharmaceuticals LLC, H1 2017

Drug Addiction – Pipeline by Heptares Therapeutics Ltd, H1 2017

Drug Addiction – Pipeline by Immunovaccine Inc, H1 2017

Drug Addiction – Pipeline by Indivior Plc, H1 2017

Drug Addiction – Pipeline by InterveXion Therapeutics LLC, H1 2017

Drug Addiction – Pipeline by Intra-Cellular Therapies Inc, H1 2017

Drug Addiction – Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017

Drug Addiction – Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017

Drug Addiction – Pipeline by MedRev Pharma, H1 2017

Drug Addiction – Pipeline by NLS Pharma Group, H1 2017

Drug Addiction – Pipeline by Omeros Corp, H1 2017

Drug Addiction – Pipeline by Opiant Pharmaceuticals Inc, H1 2017

Drug Addiction – Pipeline by Orexigen Therapeutics Inc, H1 2017

Drug Addiction – Pipeline by P2D Bioscience, H1 2017

Drug Addiction – Pipeline by Saniona AB, H1 2017

Drug Addiction – Pipeline by Savant HWP Inc, H1 2017

Drug Addiction – Pipeline by Stada Arzneimittel AG, H1 2017

Drug Addiction – Pipeline by Teva Pharmaceutical Industries Ltd, H1 2017

Drug Addiction – Pipeline by Zynerba Pharmaceuticals Inc, H1 2017

Drug Addiction – Dormant Projects, H1 2017

Drug Addiction – Dormant Projects, H1 2017 (Contd..1), H1 2017

Drug Addiction – Dormant Projects, H1 2017 (Contd..2), H1 2017

Drug Addiction – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Drug Addiction, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports